-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Friday, October 14, at 10:00 AM EDT, and Tuesday October 18, at 1:00PM CDT. Biofrontera Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
"These virtual presentations are the first in a series focused on investors in different parts of the United States. In the coming weeks, we plan similar presentations on a regular basis, aiming to inform a broad investor base about Biofrontera's business strategy and recent corporate developments", said Erica Monaco, CEO of Biofrontera Inc.
The presentations will feature Prof. Hermann Luebbert, Executive Chairman and Erica Monaco, CEO. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in one of these events will need to register using the links below. As a reminder, registration for the live event may be limited, but access to the replay after the event will be on the company's investor page.
REGISTER HERE:
Friday, October 14, 2022:
Tuesday, October 18, 2022:
- To ensure smooth connectivity, please access this link using the latest version of Google Chrome.
About Biofrontera Inc.
Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. Biofrontera, Inc. was founded in March 2015 to commercialize the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride) gel, 10%, in the United States. In 2019, Biofrontera Inc. expanded its U.S.-product portfolio with the FDA-approved drug Xepi® (ozenoxacin) cream, 1%. With both FDA-approved products, Biofrontera Inc. is ideally positioned for sustainable growth.
About Renmark Financial Communications Inc.
Founded in 1999, Renmark Financial Communications Inc. is North America's leading retail investor relations firm. Employing a strategic and comprehensive mix of exposure tactics; Renmark hosts Virtual Non-Deal Roadshows as well as in-person corporate presentations and maintains daily communications with thousands of brokers and money managers across Canada and the United States. Renmark empowers its publicly traded clientele to maximize their visibility within the financial community and strengthen their investor audience.
CONTACT:
Renmark Financial Communications Inc.
Robert Thaemlitz: rthaemlitz@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
Biofrontera Inc.
us-ir@biofrontera.com
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Friday, October 14, at 10:00 AM EDT, and Tuesday October 18, at 1:00PM CDT. Biofrontera Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
马萨诸塞州沃本，2022年10月12日(Global Newswire)--Biofrontera Inc.(以下简称“Biofrontera”或“公司”)(纳斯达克股票代码：BFRI)今天宣布，他们将参加Renmark Financial Communications Inc.的LIVE虚拟非交易路演系列活动，讨论其最新的投资者演示，时间为美国东部时间10月14日(星期五)上午10：00和美国东部时间10月18日(星期二)下午1：00。Biofrontera Inc.欢迎利益相关者、投资者和其他个人关注者注册并参加这一现场活动。
"These virtual presentations are the first in a series focused on investors in different parts of the United States. In the coming weeks, we plan similar presentations on a regular basis, aiming to inform a broad investor base about Biofrontera's business strategy and recent corporate developments", said Erica Monaco, CEO of Biofrontera Inc.
Biofrontera Inc.首席执行官埃里卡·摩纳哥表示：“这些虚拟演示是针对美国不同地区投资者的系列演示中的第一个。在接下来的几周里，我们计划定期举行类似的演示，旨在让广大投资者了解Biofrontera的业务战略和最近的公司发展。”
The presentations will feature Prof. Hermann Luebbert, Executive Chairman and Erica Monaco, CEO. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in one of these events will need to register using the links below. As a reminder, registration for the live event may be limited, but access to the replay after the event will be on the company's investor page.
主讲人包括执行主席赫尔曼·吕伯特教授和首席执行官埃里卡·摩纳哥。将涵盖的主题将包括最新的投资者演示文稿，然后是现场问答。有兴趣参加其中一项活动的投资者需要使用以下链接进行注册。提醒一下，现场活动的注册可能会受到限制，但活动结束后的重播将在该公司的投资者页面上进行。
REGISTER HERE:
请在此处注册：
Friday, October 14, 2022:
2022年10月14日(星期五)：
Tuesday, October 18, 2022:
十月一日(星期二)8, 2022:
-
To ensure smooth connectivity, please access this link using the latest version of Google Chrome.
-
为确保连接顺畅，请使用最新版本的Google Chrome访问此链接。
About Biofrontera Inc.
Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. Biofrontera, Inc. was founded in March 2015 to commercialize the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride) gel, 10%, in the United States. In 2019, Biofrontera Inc. expanded its U.S.-product portfolio with the FDA-approved drug Xepi® (ozenoxacin) cream, 1%. With both FDA-approved products, Biofrontera Inc. is ideally positioned for sustainable growth.
关于Biofrontera公司
Biofrontera是一家总部位于美国的生物制药公司，将专注于光动力疗法和局部抗生素领域的一系列药物产品商业化。在与医疗保健提供者的合作中，我们完全致力于推进治疗选择和患者护理。Biofrontera，Inc.成立于2015年3月，旨在将FDA批准的旗舰药物Ameluz商业化®(氨基乙酰丙酸盐酸盐)凝胶，10%，在美国。2019年，Biofrontera Inc.通过FDA批准的药物Xepi扩大了其在美国的产品组合®(奥美沙星)乳膏，1%。凭借这两种FDA批准的产品，Biofrontera Inc.是实现可持续增长的理想选择。
About Renmark Financial Communications Inc.
Founded in 1999, Renmark Financial Communications Inc. is North America's leading retail investor relations firm. Employing a strategic and comprehensive mix of exposure tactics; Renmark hosts Virtual Non-Deal Roadshows as well as in-person corporate presentations and maintains daily communications with thousands of brokers and money managers across Canada and the United States. Renmark empowers its publicly traded clientele to maximize their visibility within the financial community and strengthen their investor audience.
关于Renmark金融通信公司
人盟金融通信公司成立于1999年，是北美领先的散户投资者关系公司。采用战略和全面的曝光策略组合；Renmark主持虚拟非交易路演以及面对面的公司演示，并与加拿大和美国的数千名经纪人和基金经理保持日常沟通。Renmark使其上市客户能够最大限度地提高他们在金融界的知名度，并加强他们的投资者受众。
CONTACT:
Renmark Financial Communications Inc.
Robert Thaemlitz: rthaemlitz@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
联系方式：
Renmark Financial Communications Inc.
罗伯特·塞姆利茨：rthaemlitz@renmarkfinial.com
电话：(416)644-2020或(212)812-7680
Biofrontera Inc.
us-ir@biofrontera.com
Biofrontera Inc.
邮箱：us-ir@biofrontera.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧